Starboard Value has taken a roughly $1 billion stake in the drugmaker and wants the struggling company to make changes to turn its performance around, The Wall Street Journal reported. Chief Executive Albert Bourla has been under pressure from investors to right the ship at Pfizer. In addition, the company’s first attempt at a weight-loss pill disappointed while competitors such as Eli Lilly and Novo Nordisk found greater success. Read More...
Starboard Value has taken a roughly $1 billion stake in the drugmaker and wants the struggling company to make changes to turn its performance around, The Wall Street Journal reported. Chief Executive Albert Bourla has been under pressure from investors to right the ship at Pfizer. In addition, the company’s first attempt at a weight-loss pill disappointed while competitors such as Eli Lilly and Novo Nordisk found greater success.
Add Comment